Monthly Patient Volumes of Buprenorphine-Waivered Clinicians in the US
- 3 August 2020
- journal article
- letter
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 3 (8) , e2014045
Abstract
Buprenorphine, which is effective in treating opioid use disorder (OUD), can be prescribed for OUD by clinicians who obtain a US Drug Enforcement Administration (DEA) X-license after completing a Substance Abuse and Mental Health Services Administration (SAMHSA)–approved training. Federal regulations currently limit these waivered clinicians to treating 30, 100, or 275 patients with buprenorphine concurrently, with clinicians able to request an increased amount if they are limited to treating 30 or 100 patients. Clinicians historically treat fewer patients with buprenorphine than their limit allows.1 Given efforts to increase buprenorphine use, this cross-sectional study examines the number of patients treated by waivered clinicians.Keywords
This publication has 4 references indexed in Scilit:
- Overcoming Barriers to Prescribing Buprenorphine for the Treatment of Opioid Use Disorder: Recommendations from Rural PhysiciansThe Journal of Rural Health, 2018
- Prescribing patterns of buprenorphine waivered physiciansDrug and Alcohol Dependence, 2017
- Why aren't physicians prescribing more buprenorphine?Journal of Substance Abuse Treatment, 2017
- Physician Capacity to Treat Opioid Use Disorder With Buprenorphine-Assisted TreatmentJAMA, 2016